HK1250236A1 - 用gdf8抑制劑增加力量和功能的方法 - Google Patents
用gdf8抑制劑增加力量和功能的方法Info
- Publication number
- HK1250236A1 HK1250236A1 HK18109657.5A HK18109657A HK1250236A1 HK 1250236 A1 HK1250236 A1 HK 1250236A1 HK 18109657 A HK18109657 A HK 18109657A HK 1250236 A1 HK1250236 A1 HK 1250236A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- functionality
- methods
- increasing strength
- gdf8 inhibitors
- gdf8
- Prior art date
Links
- 101100228739 Danio rerio mstnb gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562147853P | 2015-04-15 | 2015-04-15 | |
US201562234899P | 2015-09-30 | 2015-09-30 | |
US201562261528P | 2015-12-01 | 2015-12-01 | |
PCT/US2016/027774 WO2016168613A1 (en) | 2015-04-15 | 2016-04-15 | Methods of increasing strength and functionality with gdf8 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1250236A1 true HK1250236A1 (zh) | 2018-12-07 |
Family
ID=55809250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18109657.5A HK1250236A1 (zh) | 2015-04-15 | 2018-07-25 | 用gdf8抑制劑增加力量和功能的方法 |
Country Status (14)
Country | Link |
---|---|
US (2) | US10934349B2 (zh) |
EP (1) | EP3283519A1 (zh) |
JP (1) | JP6877357B2 (zh) |
KR (1) | KR20170135967A (zh) |
CN (1) | CN107771081A (zh) |
AU (1) | AU2016249015B2 (zh) |
CA (1) | CA2982810A1 (zh) |
EA (1) | EA201792298A1 (zh) |
HK (1) | HK1250236A1 (zh) |
IL (1) | IL255010B2 (zh) |
MA (1) | MA49661A (zh) |
MX (1) | MX2017013267A (zh) |
WO (1) | WO2016168613A1 (zh) |
ZA (1) | ZA201707550B (zh) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007114319A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 抗体の血中動態を制御する方法 |
RU2510400C9 (ru) | 2007-09-26 | 2014-07-20 | Чугаи Сейяку Кабусики Кайся | Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr |
CN102056946A (zh) | 2008-04-11 | 2011-05-11 | 中外制药株式会社 | 与多个分子的抗原反复结合的抗原结合分子 |
KR102568454B1 (ko) | 2010-11-30 | 2023-08-18 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
ES2663946T3 (es) | 2011-11-14 | 2018-04-17 | Regeneron Pharmaceuticals, Inc. | Composiciones y métodos para aumentar la masa y la fuerza muscular antagonizando específicamente GDF8 y/o Activina A |
JP6774164B2 (ja) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
TW202340236A (zh) | 2012-08-24 | 2023-10-16 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
AU2014250434B2 (en) | 2013-04-02 | 2019-08-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素a之抗體及其用途 |
AU2015342936B2 (en) | 2014-11-06 | 2020-10-08 | Scholar Rock, Inc. | Anti-pro/latent-Myostatin antibodies and uses thereof |
TWI779010B (zh) | 2014-12-19 | 2022-10-01 | 日商中外製藥股份有限公司 | 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法 |
MX2017008978A (es) | 2015-02-05 | 2017-10-25 | Chugai Pharmaceutical Co Ltd | Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos. |
AU2016249015B2 (en) | 2015-04-15 | 2022-03-24 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with GDF8 inhibitors |
EP3350220B1 (en) | 2015-09-15 | 2021-05-19 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
WO2017218592A1 (en) * | 2016-06-13 | 2017-12-21 | Scholar Rock, Inc. | Use of myostatin inhibitors and combination therapies |
AU2017305073B2 (en) | 2016-08-05 | 2024-02-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for prevention or treatment of IL-8 related diseases |
ES2944357T3 (es) | 2017-01-06 | 2023-06-20 | Scholar Rock Inc | Tratamiento de enfermedades metabólicas inhibiendo la activación de miostatina |
MX2020008991A (es) * | 2018-03-01 | 2020-12-10 | Regeneron Pharma | Metodos para alterar la composicion corporal. |
US20220220213A1 (en) * | 2018-12-18 | 2022-07-14 | Regeneron Pharmaceuticals, Inc. | Compositions and Methods for Enhancing Body Weight and Lean Muscle Mass Using Antagonists Against Leptin Receptor, GDF8 and Activin A |
CN111303280B (zh) * | 2020-03-22 | 2022-01-07 | 中国人民解放军军事科学院军事医学研究院 | 高中和活性抗SARS-CoV-2全人源单克隆抗体及应用 |
US20230390296A1 (en) | 2020-10-30 | 2023-12-07 | Keio University | Novel treatment and prevention of sarcopenia-related diseases |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1910220A (en) * | 1931-10-21 | 1933-05-23 | Kremser Alois | Mechanically operated gate |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE69233254T2 (de) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
DE69432815T2 (de) | 1993-03-19 | 2003-12-11 | Univ Johns Hopkins Med | Wachstumsfaktor-8 |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
CA2331410C (en) | 1998-05-06 | 2009-07-14 | Metamorphix, Inc. | Methods for treating diabetes by inhibiting gdf-8 |
TR200200133T2 (tr) | 1999-07-20 | 2002-05-21 | Pharmexa A/S | GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem. |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
MXPA05012965A (es) | 2003-06-02 | 2006-03-09 | Wyeth Corp | Uso de inhibidores de miostatina (gdf8) en conjuncion con corticoesteroides para el tratamiento de desordenes neuromusculares y composiciones farmaceuticas para ello. |
AU2004312411B8 (en) | 2003-12-31 | 2011-11-24 | Schering-Plough Pty. Limited | Neutralizing epitope-based growth enhancing vaccine |
WO2005084699A1 (en) | 2004-03-02 | 2005-09-15 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors and uses thereof |
KR20060133049A (ko) | 2004-03-23 | 2006-12-22 | 일라이 릴리 앤드 캄파니 | 항-마이오스타틴 항체 |
JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー/エスGenmab A/S | Cd20に対するヒトモノクローナル抗体 |
US20060034831A1 (en) | 2004-08-12 | 2006-02-16 | Wyeth | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors |
NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
JP2008539241A (ja) | 2005-04-25 | 2008-11-13 | ファイザー インコーポレイティッド | ミオスタチンに対する抗体 |
EP1773041A1 (en) | 2005-07-21 | 2007-04-11 | Chao-Hung Wu | Audio/video data transmission system using the internet to interconnect telephones |
SI2407486T1 (en) | 2005-08-19 | 2018-04-30 | Wyeth Llc | Antagonist antibodies against GDF-8 and use in the treatment of ALS and other disorders associated with GDF-8 |
AU2006302494B2 (en) | 2005-10-06 | 2011-01-06 | Eli Lilly And Company | Anti-myostatin antibodies |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
AU2006321906C1 (en) | 2005-12-06 | 2014-01-16 | Amgen Inc. | Uses of myostatin antagonists |
CA2652976C (en) | 2006-06-02 | 2015-08-11 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
AU2007292555B2 (en) | 2006-09-05 | 2012-05-31 | Eli Lilly And Company | Anti-myostatin antibodies |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
PT2207775E (pt) | 2007-11-05 | 2012-05-11 | Novartis Ag | Derivados de 4-benzilamino-1-carboxiacil-piperidina como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose |
DK3494986T3 (da) | 2008-08-14 | 2020-08-03 | Acceleron Pharma Inc | GDF fanger |
TW201029662A (en) * | 2008-12-19 | 2010-08-16 | Glaxo Group Ltd | Novel antigen binding proteins |
EA027071B1 (ru) | 2009-04-27 | 2017-06-30 | Новартис Аг | АНТИТЕЛО К ActRIIB И СОДЕРЖАЩАЯ ЕГО КОМПОЗИЦИЯ |
EP3916011A1 (en) | 2009-06-26 | 2021-12-01 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
AU2010322011B2 (en) | 2009-11-17 | 2016-03-31 | Acceleron Pharma Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
AR081556A1 (es) | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | Proteinas de union al antigeno humanizadas |
KR20140005864A (ko) | 2010-08-16 | 2014-01-15 | 암젠 인코퍼레이티드 | 미오스타틴에 결합하는 항체, 조성물 및 방법 |
CA2817008A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma Inc. | Actriia binding agents and uses thereof |
ES2663946T3 (es) | 2011-11-14 | 2018-04-17 | Regeneron Pharmaceuticals, Inc. | Composiciones y métodos para aumentar la masa y la fuerza muscular antagonizando específicamente GDF8 y/o Activina A |
GR1007832B (el) | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
CN104487453B (zh) * | 2012-06-15 | 2018-09-28 | 辉瑞公司 | 经改良的抗gdf-8的拮抗剂抗体及其用途 |
TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素a之抗體及其用途 |
TN2016000057A1 (en) * | 2013-08-14 | 2017-07-05 | Novartis Ag | Methods of treating sporadic inclusion body myositis |
AU2016249015B2 (en) | 2015-04-15 | 2022-03-24 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with GDF8 inhibitors |
-
2016
- 2016-04-15 AU AU2016249015A patent/AU2016249015B2/en active Active
- 2016-04-15 EP EP16718831.7A patent/EP3283519A1/en active Pending
- 2016-04-15 JP JP2017553974A patent/JP6877357B2/ja active Active
- 2016-04-15 CA CA2982810A patent/CA2982810A1/en active Pending
- 2016-04-15 KR KR1020177032792A patent/KR20170135967A/ko not_active IP Right Cessation
- 2016-04-15 IL IL255010A patent/IL255010B2/en unknown
- 2016-04-15 MX MX2017013267A patent/MX2017013267A/es unknown
- 2016-04-15 WO PCT/US2016/027774 patent/WO2016168613A1/en active Application Filing
- 2016-04-15 CN CN201680035382.9A patent/CN107771081A/zh active Pending
- 2016-04-15 US US15/099,701 patent/US10934349B2/en active Active
- 2016-04-15 MA MA049661A patent/MA49661A/fr unknown
- 2016-04-15 EA EA201792298A patent/EA201792298A1/ru unknown
-
2017
- 2017-11-08 ZA ZA2017/07550A patent/ZA201707550B/en unknown
-
2018
- 2018-07-25 HK HK18109657.5A patent/HK1250236A1/zh unknown
-
2021
- 2021-01-14 US US17/149,540 patent/US20210246198A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL255010A0 (en) | 2017-12-31 |
US10934349B2 (en) | 2021-03-02 |
JP6877357B2 (ja) | 2021-05-26 |
MA49661A (fr) | 2020-06-03 |
US20210246198A1 (en) | 2021-08-12 |
EA201792298A1 (ru) | 2018-04-30 |
AU2016249015A1 (en) | 2017-11-09 |
JP2018512435A (ja) | 2018-05-17 |
MX2017013267A (es) | 2018-08-15 |
IL255010B2 (en) | 2024-01-01 |
EP3283519A1 (en) | 2018-02-21 |
CA2982810A1 (en) | 2016-10-20 |
CN107771081A (zh) | 2018-03-06 |
US20160304595A1 (en) | 2016-10-20 |
ZA201707550B (en) | 2018-11-28 |
KR20170135967A (ko) | 2017-12-08 |
IL255010B1 (en) | 2023-09-01 |
WO2016168613A1 (en) | 2016-10-20 |
AU2016249015B2 (en) | 2022-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1250236A1 (zh) | 用gdf8抑制劑增加力量和功能的方法 | |
IL283353A (en) | hpk1 inhibitors and methods of using them | |
IL286316A (en) | New micro-dystrophins and related method of use | |
HK1258058A1 (zh) | 抗tigit抗體和使用方法 | |
HK1252858A1 (zh) | 抗cll-1抗體和使用方法 | |
HK1247569A1 (zh) | 抗pvrig抗體和使用方法 | |
HK1246286A1 (zh) | Lrrk2抑制劑及其製備和使用方法 | |
HK1253049A1 (zh) | 糖基相互作用化合物及其使用方法 | |
GB201514756D0 (en) | Compound and method of use | |
IL282482A (en) | Variants of protoxin-II and methods of use | |
IL282508A (en) | Variants of protoxin-II and methods of use | |
GB201421894D0 (en) | End fitting and method of manufacture | |
HK1256368A1 (zh) | 加利車黴素-抗體-藥物綴合物和使用方法 | |
HK1258850A1 (zh) | 抗tpbg抗體及使用方法 | |
GB2556242B (en) | Asphaltene dispersant and methods of use thereof | |
HK1250360A1 (zh) | 袋和製作袋的方法 | |
IL242952A0 (en) | An array of detectors and a method to create it | |
GB201419990D0 (en) | Hprseshoe and method of manufacture | |
GB201416797D0 (en) | Contianer and method of use thereof |